Frequency Therapeutics, Inc. (NasdaqGS: FREQ) Loss Submission Form

Kuzincki Law is investigating the proposed sale of Frequency Therapeutics, Inc. (NasdaqGS: FREQ) to Korro Bio, Inc.  Under the terms of the proposed transaction, pre-merger Frequency Therapeutics stockholders are expected to own approximately 8% of the combined company. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.